CD8A and neoplasm: Despite the benefits of ICB in multiple difficult-to-treat cancer types, the majority of cancers showed primary and acquired resistance to ICB therapy [59,60], suggesting more complicated molecular and cellular mechanisms beyond CD8+ T cells mediating tumor immune escape in the TME.